← Leaderboards
Dianne M Perez
Cleveland Clinic Foundation
$6,393,962
Attributed
$6,393,962
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $476.4K · FY2005–24$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$6,393,962 · 4
By mechanism
R01$6,235,462 · 3
R03$158,500 · 1
Top collaborators
No co-investigators on record.
Most similar at Cleveland Clinic Foundation
Same institution · by research overlap
- Ram N. Ganapathi$3,109,959
- Dan F McCune$81,280
- Derek Scott Damron$2,722,767
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposBlood PressureLightClinical TrialsPharmaceutical PreparationsPublishingSignal TransductionAdrenergic ReceptorChronicLeadLaboratoriesReceptor BindingNerve DegenerationG-Protein-Coupled ReceptorsEpinephrineLigandsNovel TherapeuticsMediatingAffinityAnimal ModelCardiacIn VitroIn VivoApoptotic
Grant awards (18)
Early Stage Studies of a Novel Positive Allosteric Modulator of the Alpha1-Adrenergic Receptor to Treat Alzheimer's Disease$402,500
R01 · FY2024 · AG · contact PI
Early Stage Studies of a Novel Positive Allosteric Modulator of the Alpha1-Adrenergic Receptor to Treat Alzheimer's Disease$402,500
R01 · FY2023 · AG · contact PI
Early Stage Studies of a Novel Positive Allosteric Modulator of the Alpha1-Adrenergic Receptor to Treat Alzheimer's Disease$402,500
R01 · FY2022 · AG · contact PI
Early Stage Studies of a Novel Positive Allosteric Modulator of the Alpha1-Adrenergic Receptor to Treat Alzheimer's Disease$402,500
R01 · FY2021 · AG · contact PI
Early Stage Studies of a Novel Positive Allosteric Modulator of the Alpha1-Adrenergic Receptor to Treat Alzheimer's Disease$402,083
R01 · FY2020 · AG · contact PI
Alpha1A-Adrenoceptors in Cognition$79,250
R03 · FY2016 · AG · contact PI
Alpha1A-Adrenoceptors in Cognition$79,250
R03 · FY2015 · AG · contact PI
Protective signaling mechanisms of the alpha1A-adrenoceptor$369,923
R01 · FY2013 · HL · contact PI
Protective signaling mechanisms of the alpha1A-adrenoceptor$388,575
R01 · FY2012 · HL · contact PI
Protective signaling mechanisms of the alpha1A-adrenoceptor$392,500
R01 · FY2011 · HL · contact PI
Protective signaling mechanisms of the alpha1A-adrenoceptor$392,500
R01 · FY2010 · HL · contact PI
Alpha1-Adrenoceptor Subtypes & Role in Pathophysiology$476,411
R01 · FY2006 · HL · contact PI
Alpha1-Adrenoceptor Subtypes &Role in Pathophysiology$473,664
R01 · FY2005 · HL
Alpha1-Adrenoceptor Subtypes &Role in Pathophysiology$459,868
R01 · FY2004 · HL
Alpha1-Adrenoceptor Subtypes &Role in Pathophysiology$378,801
R01 · FY2003 · HL
ALPHA1 ADRENOCEPTOR SUBTYPES AND ROLE IN PATHOPHYSIOLOGY$335,156
R01 · FY2002 · HL
ALPHA1 ADRENOCEPTOR SUBTYPES AND ROLE IN PATHOPHYSIOLOGY$325,396
R01 · FY2001 · HL
ALPHA1 ADRENOCEPTOR SUBTYPES AND ROLE IN PATHOPHYSIOLOGY$230,585
R01 · FY2000 · HL